

I hereby certify that, on the date shown below, this correspondence is being:  
 deposited with the United States Postal Service in an envelope addressed to:  
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,  
 under 37CFR § 1.8(a), with sufficient postage as first class mail, or  
 under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label  
No. \_\_\_\_\_  
 transmitted by facsimile to the Patent and Trademark Office, Fax Number  
\_\_\_\_\_, Attention: Examiner \_\_\_\_\_

PATENT

Attorney Docket No.  
DX0724XK1

CN 028008

Date: 4-30, 2002 By: Lois E. Miller  
Lois E. Miller



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE #7

re application of:

Gereard T. HARDIMAN, et al.

Serial No.: 09/950,041

Filed: September 10, 2002

For: HUMAN RECEPTOR PROTEINS;  
RELATED REAGENTS AND  
METHODS

Examiner: not yet assigned

Art Unit: 1653

INFORMATION DISCLOSURE  
STATEMENT

Palo Alto, California 94304

APRIL 29, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The materials as listed in the attached modified PTO 1449 form are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Also enclosed please find a copy of the PCT Search Report dated November 11, 1998. Applicants have included "X" designated references listed in the PCT Search Report in the attached 1449 Forms.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that an exhaustive search has been made or that more pertinent art may not be in existence.


**PATENT**

Applicants request that the Examiner fully consider the art cited in the attached modified PTO 1449 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Since this Information Disclosure Statement is being filed before receiving the first Office action, applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute's Deposit Account No. 04-1239.

Respectfully submitted,

By:

  
Sheela Mohan-Peterson  
Attorney for Applicants  
Reg. No. 41,201

Enclosures: Modified PTO 1449 form (4 pages)  
PCT Search Report dated November 17, 1998 (14 pages)  
References AA-B (52 refs.)